{"contentid": 488240, "importid": NaN, "name": "GSK sells royalty rights on cancer drugs for nearly $400 million", "introduction": "UK pharma major GlaxoSmithKline has reached agreement to sell its royalty interest in two cabozantinib products, brand names Cabometyx and Cometriq, to Royalty Pharma.", "content": "<p>UK pharma major GlaxoSmithKline (LSE: GSK) has reached agreement to sell its royalty interest in two cabozantinib products, brand names Cabometyx and Cometriq, to Royalty Pharma (Nasdaq: RPRX).</p>\n<p>Under the terms of the deal, GSK will receive an upfront payment of $342 million and up to $50 million in additional payments contingent on the achievement of regulatory approvals of cabozantinib for prostate cancer and lung cancer in the USA and Europe.</p>\n<p>Cabometyx, a multi-tyrosine kinase inhibitor (TKI), is approved for the treatment of patients with advanced renal cell carcinoma (RCC) both as monotherapy and in combination with Bristol Myers Squibb&rsquo;s (NYSE: BMY) Opdivo (nivolumab) as a first line treatment. Cabometyx is also approved for hepatocellular carcinoma (HCC) in patients previously treated with sorafenib. Cometriq is approved for progressive, metastatic medullary thyroid cancer. Cabometyx and Cometriq are marketed by Exelixis (Nasdaq: EXEL) in the USA, and by partner partner Ipsen (Euronext: IPN) in regions outside the USA and Japan. Cabometyx is marketed in Japan by Exelixis&rsquo; partner Takeda (TYO: 4502).</p>\n<h2><strong>GSK deal with Exelixis</strong></h2>\n<p>GSK is entitled to a 3% royalty on worldwide net sales of cabozantinib products as a result of its 2002 collaboration with Exelixis. Under this transaction&rsquo;s terms, Royalty Pharma has purchased royalties on cabozantinib products&rsquo; net sales in non-US markets through the full term of the royalty and royalties on net sales in the USA through September 2026, after which US royalties will remain with GSK.</p>\n<p>In 2020, sales of Cabometyx and Cometriq reported by Exelixis and Ipsen were $742 million and 289 million euros ($340 million), respectively.</p>\n<p>&ldquo;We are delighted to acquire this royalty stream from GSK,&rdquo; said Pablo Legorreta, founder and chief executive of Royalty Pharma, adding: &ldquo;Cabometyx is a leading TKI for the treatment of advanced kidney and liver cancer. The recent US approval for the first line treatment of advanced kidney cancer in combination with Opdivo represents an important advance for patients to improve treatment outcomes and quality of life.&rdquo;</p>", "date": "2021-04-02 11:22:00", "meta_title": "GSK sells royalty rights on cancer drugs for nearly $400 million", "meta_keywords": "GlaxoSmithKline, Royalty Pharma, Exelixis, Cabozantinib, Cabometyx, Cometriq, Royalty interest", "meta_description": "GSK sells royalty rights on cancer drugs for nearly $400 million", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-02 11:21:23", "updated": "2021-04-02 11:35:37", "access": NaN, "url": "https://www.thepharmaletter.com/article/gsk-sells-royalty-rights-on-cancer-drugs-for-nearly-400-million", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "gsk_large.jpg", "image2id": "gsk_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology, Oncology", "topic_tag": "Deals, Financial", "geography_tag": "UK, USA", "company_tag": "Exelixis, GlaxoSmithKline, Royalty Pharma", "drug_tag": "Cabometyx, cabozantinib, Cometriq", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-02 11:22:00"}